CTX310

Oct. 8, 2026: CRISPR Therapeutics (NASDAQ: CRSP) said Phase 1b data for CTX310, its in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3, will be presented in a late-breaking oral session at the American Heart Association Scientific Sessions 2026. The presentation, titled “CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial,” is scheduled for November 9, 2026 at 8:00 a.m. CST in the session “LBS.05 New Frontiers in Cardiometabolic Risk Reduction.”

The company said the abstract and presentation data are under embargo until the presentation time, and the slides will be posted on its website after the session.

The release also outlines CRISPR Therapeutics’ in vivo liver-editing pipeline: CTX310 for heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia; CTX340 targeting AGT for refractory hypertension; CTX321 targeting LPA for elevated lipoprotein(a); and CTX460 targeting SERPINA1 using SyNTase editing for alpha-1 antitrypsin deficiency.